Insider TradingJul 22, 2026, 10:02 AM
OKYO Pharma Director Gary Jacob Increases Shareholdings by 3,500
AI Summary
OKYO Pharma Ltd announced that Gary S. Jacob, Chief Development Officer and Director, increased his stake in the company by purchasing 3,500 ordinary shares at $1.40 each. This transaction brings his total holdings to 112,420 shares, signaling confidence in the biopharmaceutical company. OKYO Pharma is focused on developing therapies for neuropathic corneal pain (NCP) and plans to initiate a Phase 3 clinical trial for urcosimod in the second half of this year.
Key Highlights
- Gary S. Jacob, Chief Development Officer and Director, purchased 3,500 ordinary shares.
- Shares were purchased on NASDAQ at $1.40 per share.
- Dr. Jacob's total holding now stands at 112,420 ordinary shares.
- OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in H2 2026.
- The Phase 3 trial will enroll approximately 111 patients.
- The trial will evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP).
Price Impact
More from OKYO